Crossmark

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Crossref DOI link: https://doi.org/10.1007/s00280-017-3417-3

Published Online: 2017-08-11

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matsubara, Nobuaki

Mukai, Hirofumi

Hosono, Ako

Onomura, Mai

Sasaki, Masaoki

Yajima, Yoko

Hashizume, Kensei

Yasuda, Masanobu

Uemura, Miho

Zurth, Christian
Funding

Funding for this research was provided by:

Bayer Yakuhin, Ltd.
License Information

License valid from 2017-08-11